AKAnna A. Kuznetsova

Anna A. Kuznetsova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna A. Kuznetsova has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Pharmacology Handbook for Obstetricians and Gynecologists. Edited by Irina E. Zazerskaya, Mikhail V. Pchelintsev, Andrei N. Kubynin

    by Irina Zazerskaya, Mikhail Pchelintsev, Андрей Николаевич Кубынин, Надежда Анатольевна Антипова, Elena Araviiskaya, Arutyun Arutyunyan, Алина Юрьевна Бабенко, Татьяна Валерьевна Батракова, Ekaterina Belyaeva, Ofeliya Bettikher, et al.

    This clinical pharmacology handbook is organized according to the nosological principle of the ICD-10 classification and contains information on the necessary diagnostic and pharmacotherapeutic measures for conditions encountered in obstetric and gynecological practice. The book describes the drugs that are approved in the Russian Federation. The systematic organization of this large body of material allows the physician to easily determine a diagnostic and treatment plan based on current guidelines, select a drug by its international nonproprietary or brand name, verify its dosage, route of administration, and therapy duration, and provide a prescription. The handbook is intended for obstetricians and gynecologists to use in their daily practice. It will also be helpful to continuing education students at the departments of obstetrics and gynecology and clinical pharmacology.

  • Prognostic risk factors for abnormally adherent and invasive placenta in women with placenta located in the area of the uterine scar

    by N.YU. Ponikarova, Saint Petersburg 2B Akkuratova Str., E.S. Shelepova, A.A. Kazanskaya, V.N. Kustarov, I.E. Zazerskaya

    Aim. To identify independent prognostic risk factors for abnormally adherent and invasive placenta (AAIP) in women with a placenta located in the area of a uterine scar. Design. Case-control study. Materials and methods. A study was conducted involving 110 women with placenta located in the area of a uterine scar, divided into two groups: the main group with placenta located in the area of the uterine scar and abnormally adherent and invasive placenta (AAIP) (n = 55) and the control group with placenta located in the area of the uterine scar without AAIP (n = 55). A retrospective analysis was performed using medical records, general and obstetric examination data, and information collected during pregnancy and at the time of hospitalization for delivery. Statistical analysis methods were used to identify significant factors. Results. Despite comparable obstetric and gynecological history, the key prognostic factors for AAIP were features of the current pregnancy: placenta previa (odds ratio (OR) = 70.7; 95% confidence interval (CI) 15.3–326.8); vaginal bleeding after 26 weeks of gestation (OR = 5.7; 95% CI 2.47–12.97); threatened late miscarriage/preterm birth in the 2nd and 3rd trimesters (OR = 4.3 and 3.5, respectively); anemia diagnosed in the 2nd trimester (OR = 2.66; 95% CI 1.2–6.1). Conclusion. In women with placenta located in the area of the uterine scar, in addition to placenta previa, independent prognostic risk factors for AAIP are late-pregnancy bleeding, threatened preterm birth in the 2nd–3rd trimesters, and 2nd-trimester anemia. The establishment of these features will improve the prenatal detection of high-risk patients. Keywords: abnormally adherent and invasive placenta, placenta located in the uterine scar, risk factors, placenta previa, obstetric hemorrhage.

  • Open Access

    Management of pregnant women with pheochromocytoma: clinical cases and literature review

    by E. S. Shelepova, N. A. Osipova, A. A. Kuznetcova, A. S. Aitkulova, R. A. Bairova, U. A. Tsoy, I. E. Zazerskaya

    Objective. To represent clinical cases of pheochromocytoma (PCC) during pregnancy and to draw attention to diagnostics, choice of proper treatment and delivery method.Design and methods. Both domestic and forensic scientific and medical publications about hypertension and PCC were analyzed. We also represent four clinical cases of the patients with PCC, who were observed and treated in Perinatal Centre of Almazov National Medical Research Centre.Results. In three cases hypertension had been diagnosed before present pregnancy, and in two cases it had been treated as essential hypertension. One woman registered increased blood pressure (BP) during pregnancy for the first time. In three cases hypertensive crises were registered. Two caesarian sections were performed because of fetoplacental circulation disorders and high risks of antenatal fetal death, both before full term. Two natural births occurred at full term and at 34 weeks due to the development of spontaneous labor. In all cases PCC was diagnosed during pregnancy, confirmed by histology and immunohistochemistry after adrenalectomy in the postpartum period.Conclusions. All patients with PCC during pregnancy must be followed by a multidisciplinary team including obstetricians, cardiologists, endocrinologists, surgeons, anesthesiologists and neonathologists. Early diagnosis and proper treatment significantly improve prognosis during pregnancy for both mother and fetus. Specialists must exclude PCC if any urgent cardiovascular situation developed during pregnancy, including first detection of increased BP.

  • Features of the prognosis and outcomes of pregnancy with massive subchorionic thrombosis. A literature review

    by Anna A. Kuznetsova, Ekatherina S. Shelepova, Natalya A. Osipova, Tatyana Yu. Roschina, Irina E. Zazerskaya

    Massive subchorionic thrombohematoma, also termed in the literature as Breus mole, is a rare condition in which a large maternal blood clot separates the chorionic plate from the chorionic villi. The etiology and pathogenesis of this condition are yet unclear, and the very concept of massive subchorionic thrombohematoma remains vague due to the singularity of clinical cases and the necessity to distinguish it from other types of hematomas. The lack of a unified view on the pathology and clear-cut clinical, laboratory and ultrasound criteria can lead to insufficient attention of doctors and untimely or even incorrect establishing diagnosis, which significantly worsens the prognosis of pregnancy and increases the risk of potential complications. Patients with massive subchorionic thrombohematoma require increased attention due to the high rate of such manifestations as antenatal death, fetal growth retardation, late miscarriage, and preeclampsia. Each case should be carefully analyzed in order to find predictors of thrombohematomas and methods of their prevention.